Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC) Meeting Abstract
| Authors: | Kudo, M.; Lencioni, R.; Erinjeri, J.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V. V.; Bouattour, M.; Dayyani, F.; Yoon, J. H.; Chiu, C. F.; Suttichaimongkol, T.; Decaens, T.; Griffin, R.; Morgan, C.; Ali, S. K.; Balaji, K.; Sangro, B. |
| Abstract Title: | Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC) |
| Meeting Title: | ESMO Asia Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2024 Dec 6-8 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-12-01 |
| Start Page: | S1480 |
| Language: | English |
| ACCESSION: | WOS:001401985200190 |
| DOI: | 10.1016/j.annonc.2024.10.220 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 199P -- Source: Wos |
